IRIS
CESARO, ARTURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.277
AS - Asia 3.232
NA - Nord America 2.371
SA - Sud America 495
AF - Africa 53
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 12.432
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 4.858
US - Stati Uniti d'America 2.311
SG - Singapore 1.157
CN - Cina 683
VN - Vietnam 530
IE - Irlanda 485
HK - Hong Kong 430
BR - Brasile 400
IT - Italia 373
DE - Germania 159
KR - Corea 145
GB - Regno Unito 129
IN - India 106
AR - Argentina 47
FR - Francia 43
MX - Messico 31
AT - Austria 30
GR - Grecia 27
JP - Giappone 27
UA - Ucraina 26
BD - Bangladesh 23
FI - Finlandia 23
SE - Svezia 23
ID - Indonesia 21
TR - Turchia 21
CA - Canada 20
NL - Olanda 20
BE - Belgio 16
PL - Polonia 15
ES - Italia 14
IQ - Iraq 14
CO - Colombia 12
EG - Egitto 12
EC - Ecuador 11
MA - Marocco 11
PK - Pakistan 11
ZA - Sudafrica 11
LT - Lituania 9
CL - Cile 7
VE - Venezuela 7
SA - Arabia Saudita 6
TH - Thailandia 6
TN - Tunisia 6
UZ - Uzbekistan 6
IR - Iran 5
KZ - Kazakistan 5
IL - Israele 4
JO - Giordania 4
NP - Nepal 4
PA - Panama 4
TW - Taiwan 4
UY - Uruguay 4
AZ - Azerbaigian 3
BG - Bulgaria 3
CH - Svizzera 3
DK - Danimarca 3
JM - Giamaica 3
KE - Kenya 3
PE - Perù 3
PH - Filippine 3
PY - Paraguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
CR - Costa Rica 2
EU - Europa 2
KG - Kirghizistan 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
HR - Croazia 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RO - Romania 1
SN - Senegal 1
SY - Repubblica araba siriana 1
UG - Uganda 1
Totale 12.432
Salva come PNG Salva come JPEG
Città #
Moscow 1.777
Singapore 560
San Jose 523
Dublin 476
Hong Kong 424
Santa Clara 358
Chandler 237
Ho Chi Minh City 176
Hefei 170
Ashburn 162
Seoul 143
Hanoi 131
New York 103
Beijing 90
Naples 78
The Dalles 77
Bengaluru 68
Princeton 51
Roxbury 51
Da Nang 41
Jacksonville 38
Los Angeles 38
Bremen 34
Nuremberg 34
Milan 33
Cambridge 30
São Paulo 28
Council Bluffs 24
Dallas 23
Des Moines 23
Medford 23
Falkenstein 21
Munich 20
Orem 20
Haiphong 18
Mexico City 17
Boardman 16
Brussels 16
Aversa 14
Rio de Janeiro 14
Frankfurt am Main 13
Helsinki 13
Tokyo 13
Ann Arbor 12
Hyderabad 12
Vienna 12
Guangzhou 11
Rome 11
Wilmington 11
Hải Dương 10
Nanjing 10
Amsterdam 9
Thái Nguyên 9
Warsaw 9
Belo Horizonte 8
Campinas 8
Chicago 8
Curitiba 8
Ercolano 8
London 8
Nha Trang 8
Ninh Bình 8
Shenzhen 8
Sivas 8
Thái Bình 8
Cairo 7
Caserta 7
Dhaka 7
Jakarta 7
Jinan 7
Baghdad 6
Brasília 6
Brooklyn 6
Can Tho 6
Salerno 6
Toronto 6
Turin 6
Bangkok 5
Belluno 5
Biên Hòa 5
Bologna 5
Buenos Aires 5
Bắc Ninh 5
Bến Tre 5
Chennai 5
Columbus 5
Guayaquil 5
Houston 5
Islamabad 5
Johannesburg 5
Lappeenranta 5
Madrid 5
Osasco 5
Phoenix 5
Porto Alegre 5
San Francisco 5
Santiago 5
Stockholm 5
Tashkent 5
Zhengzhou 5
Totale 6.615
Salva come PNG Salva come JPEG
Nome #
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 180
Advanced Heart Failure in Special Population—Pediatric Age 174
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 162
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 161
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 155
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 155
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 152
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 151
Diagnosis and Management of Cardiovascular Involvement in Fabry Disease 150
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 148
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 145
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 136
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 136
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 135
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 131
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 129
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 129
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 127
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials 127
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 127
The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases 126
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 124
SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes 124
Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy 123
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 122
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 122
Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approach 122
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 122
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 122
Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge 122
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes 121
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 120
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 120
Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis 119
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque 116
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 115
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 115
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial 112
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 112
SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction 111
Circulating culprit or therapeutic bullseye: lipoprotein(a) in cardiovascular risk assessment and novel therapeutic prospects 111
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 109
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 109
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 107
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 107
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 106
Early-onset MINOCA: Prognostic implications and considerations for practice 106
Ipercolesterolemia e referti di laboratorio: documento congiunto della Società Italiana di Cardiologia (SIC) e Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica - Medicina di Laboratorio (SIBioC) 105
Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent 105
A pragmatic approach for thrombotic prevention after acute coronary syndromes 104
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 104
The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review 104
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 104
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 104
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 102
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 101
[Long COVID: nosographic aspects and clinical epidemiology] 101
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 100
Coronary stent thickness: thinner is (always) better for all lesions? 100
Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT) 99
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 99
The Biological Role of Vitamins in Athletes’ Muscle, Heart and Microbiota 99
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 99
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention 98
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 94
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 93
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 93
null 93
Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference 93
Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 92
Beyond the left ventricle: Why the right heart matters in Takotsubo syndrome 92
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 92
Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis? 92
Artificial intelligence in cardiovascular prevention: new ways will open new doors 91
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 91
Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol 91
The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers 90
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 90
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 89
Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): A meta-analysis 89
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 88
How has COVID-19 impacted the care of patients with acute coronary syndromes? 87
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 87
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 87
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 86
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 85
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve 85
Epigenetic mechanisms underlying the beneficial effects of cardiac rehabilitation. An overview from the working groups of “cellular and molecular biology of the heart” and “cardiac rehabilitation and cardiovascular prevention” of the Italian Society of Cardiology (SIC) 83
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 83
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome 82
The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia 82
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein? 81
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study 81
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey 81
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 80
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease 79
Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry) 78
Reply to SGLT-2 inhibitors: Post-infarction interventional effects 77
Geographic variations in percutaneous versus surgical coronary revascularization: A global perspective from the SYNTAXES trial 77
Laboratory medicine: health evaluation in elite athletes 77
Totale 10.894
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.542
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.542
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202146 0 0 0 0 0 0 0 0 0 7 30 9
2021/2022430 9 3 8 17 104 10 10 41 9 55 37 127
2022/2023863 84 56 19 59 77 46 2 57 428 5 14 16
2023/2024513 28 17 20 24 129 111 19 12 4 29 13 107
2024/20251.804 8 13 2 54 251 207 231 170 259 276 172 161
2025/20268.846 359 526 487 418 678 4.569 606 589 364 250 0 0
Totale 12.716